Last reviewed · How we verify
Arm 2：Fixed Delay Group
At a glance
| Generic name | Arm 2：Fixed Delay Group |
|---|---|
| Also known as | PD-1 Delayed Administration on D3 (Fixed Delay Group) Participants in this group will receive chemotherapy on D1 and then receive the PD-1 inhibitor on D3 of each cycle. |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Urgent Carotid Endarterectomy (CEA) Versus Delayed CEA in Symptomatic Carotid Stenosis (SPREAD-STACI II) (NA)
- Lung Ultrasound-Guided Positioning Strategy for the Prevention of Ventilator-Associated Pneumonia in Neonates (NA)
- Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial (PHASE1, PHASE2)
- CTNNB1 Neurodevelopmental Syndrome - Natural History Study
- Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR) (PHASE2)
- A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device (NA)
- Intervention Trial to Increase Meaning in Work and Reduce Burnout (NA)
- A Study to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments to Promote Tissue Healing (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |